Lineage Cell Therapeutics (NASDAQ:LCTX) insider Brian M. Culley purchased 10,000 shares of the stock in a transaction on Tuesday, August 13th. The stock was acquired at an average cost of $1.01 per share, with a total value of $10,100.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Lineage Cell Therapeutics stock remained flat at $$0.92 during mid-day trading on Friday. Lineage Cell Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.81.

Lineage Cell Therapeutics (NASDAQ:LCTX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $0.78 million for the quarter, compared to analyst estimates of $1.04 million.

Separately, Maxim Group set a $3.00 price target on shares of Lineage Cell Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 9th.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Further Reading: What are the benefits of momentum investing?

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with's FREE daily email newsletter.